Cell-based therapy with cells of the mesenchymal sub-type is a highly effective strategy for vascular rejuvenation, immunomodulation, and reduction of fibrosis. Clinical data has accumulated that strongly supports this underlying mechanism of action in a variety of disease areas. Future trials designed based on these mechanistic concepts should advance this exciting therapeutic area.

Joshua Hare is a board-certified practicing Cardiologist and holds the Louis Lemberg Professorship of Medicine at the University of Miami Miller School of Medicine. Dr. Hare is the co-founder/Chairman of Longeveron, Inc., (LGVN) a NASDAQ listed biotechnology company. Dr. Hare currently directs the Heart Transplantation Program at the Jackson Memorial Hospital and is the founding Director of the Interdisciplinary Stem Cell Institute at the University of Miami. Dr. Hare is a widely published and has authored over 445 articles in the Medical Literature (H-index is 119) and has been awarded multiple Patents for his discoveries internationally. Dr. Hare has pioneered the use as cells as medicines for human heart disease, Alzheimer’s disease, Stroke and diseases of aging. His research has been funded by the National Institutes of Health and the Department of Defense. Longeveron (LGVN), which went public in 2021, is conducting research internationally into using cells as treatments for Alzheimer’s Disease, Aging Frailty, and congenital heart diseases, and has received funding from the Alzheimer’s Association and the National Institutes of Aging. Hare is an inducted member of the American Association of Physicians and the National Academy of Inventors.